Patents by Inventor David R. Koos

David R. Koos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans
    Publication number: 20220249436
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.
    Type: Application
    Filed: March 18, 2022
    Publication date: August 11, 2022
    Applicant: KCL THERAPEUTICS, INC
    Inventors: Harry M. Lander, David R. Koos
  • Small molecule agonists and antagonists of NR2F6 activity
    Patent number: 11377442
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: July 5, 2022
    Assignee: Zander Biologics, Inc
    Inventors: Harry M. Lander, David R. Koos
  • Small molecule agonists and antagonists of NR2F6 activity in humans
    Patent number: 11324719
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 10, 2022
    Assignee: KCL Therapeutics, Inc.
    Inventors: Harry M. Lander, David R. Koos
  • SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS
    Publication number: 20200071307
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 5, 2020
    Applicant: ZANDER THERAPEUTICS, INC.
    Inventors: Harry M. Lander, David R. Koos
  • Small molecule agonists and antagonists of NR2F6 activity in animals
    Patent number: 10472351
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: November 12, 2019
    Assignee: Zander Therapeutics, Inc.
    Inventors: Harry M. Lander, David R. Koos
  • Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals
    Publication number: 20190054118
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.
    Type: Application
    Filed: November 21, 2017
    Publication date: February 21, 2019
    Inventors: Harry M. Lander, David R. Koos
  • SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS
    Publication number: 20180346455
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 6, 2018
    Inventors: Harry M. Lander, David R. Koos
  • SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY
    Publication number: 20180346456
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 6, 2018
    Inventors: Harry M. Lander, David R. Koos
  • Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans
    Publication number: 20180214413
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.
    Type: Application
    Filed: November 21, 2017
    Publication date: August 2, 2018
    Inventors: Harry M. Lander, David R. Koos